The milestone structure is the story: almost all of that headline number is contingent on undisclosed drug targets and an unproven autoimmune indication, making this a deliberate option bet rather than a de risked asset purchase.
Boulevard Bio, a Deerfield-backed biotech, is paying $20 million upfront and promising up to roughly $1.6 billion in milestones to license global rights to MTS-128, a preclinical three-target immune-cell drug from Hong Kong-listed METiS TechBio. The shape of the deal matters as much as the price: $20 million in real cash against $1.6 billion in contingent milestones is the financial signature of an option bet, not the price tag on a derisked asset.
The drug class in question is a T-cell engager, a category that has been a workhorse of blood cancer treatment for years. Bispecific T-cell engagers such as the CD19xCD3 class bind a patient's T-cells on one arm and a tumor antigen on the other, forcing the immune cell to kill the diseased target. MTS-128 is a step further along: a trispecific T-cell engager, meaning it carries three binding arms instead of two. Fierce Biotech reported the deal terms and the undisclosed target identities, and METiS's June 30 Hong Kong stock exchange filing confirms the autoimmune framing but does not name the three drug targets or the specific autoimmune disease.
The category shift that justifies the structure is real. Earlier this month, Cullinan Therapeutics posted systemic lupus erythematosus data on a T-cell engager, the first credible autoimmune peer datapoint of 2026. A disclosed scientific precedent for trispecific TCEs already exists: CC312, a trispecific CD19-targeting co-stimulatory T-cell engager reported at AACR 2025, was tested in B-cell malignancies and autoimmune disease. Boulevard Bio is not buying a de-risked program; it is buying a stake in the question of whether cancer's immune-cell-redirecting playbook can be transplanted into autoimmune disease.
The oncology benchmark is also clear. In 2026 dealmaking, Astellas signed a $1.7 billion collaboration with Vir Biotechnology for a prostate cancer T-cell engager, and Boehringer Ingelheim lists the modality high on its shopping list. The Astellas deal values a clinical-stage oncology TCE; the Boulevard–METiS deal prices a preclinical trispecific autoimmune TCE with hidden targets. The ratio is the story: roughly the same headline number, but Boulevard Bio is paying almost all of it in contingent milestones rather than committed capital.
METiS TechBio is not a target-discovery company. Its pitch, per the company's About page, is AI-driven formulation and delivery, including what it markets as "the world's first AI-driven nano-delivery platform" and "the world's largest proprietary LNP lipid library with over 10 million lipids." That language is METiS's own marketing and is not independently validated in the current reference set. METiS was founded in 2020, IPO'd on the Hong Kong stock exchange the month before this deal was announced, and operates out of Hangzhou, Beijing, Shanghai and Cambridge, Massachusetts, according to the same site. Selling a preclinical autoimmune asset to a Deerfield-backed U.S. vehicle is, in that light, a meaningful cross-border capital path for a Chinese biotech whose core competency is formulation rather than target biology.
What to watch now: METiS's next Hong Kong disclosure or scientific meeting appearance that names MTS-128's three targets, the disclosure of the autoimmune indication, and any IND-enabling toxicology work that would move the program into the clinic. Until then, the PatSnap Synapse profile on MTS-128 lists no clinical trials and no disclosed indications, which is what the deal price is actually pricing.